FDA Examines AI Potential in Health Care, Product Supply Chain

Oct. 15, 2024, 5:00 PM UTC

Artificial intelligence is likely to play a crucial role in medical supply chain management and continue to transform product development, but FDA officials say strong agency oversight is needed to protect the long-term success of industries.

The FDA will continue to play a central role in evaluating AI tools to improve health-care and biomedicine, but all involved entities will need to be equipped with the rigor that the transformative technology merits, high-ranking officials for the Food and Drug Administration wrote Tuesday in a JAMA Network Special Communication.

The analysis reviewed the history of the FDA’s AI regulation and outlined ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.